((“ovarian cancer” OR “endometrial cancer” OR “cervical cancer” OR “gynecologic cancer”) AND (“PD-1” OR “PD-L1” OR “immune checkpoint inhibitor” OR pembrolizumab OR nivolumab OR durvalumab OR dostarlimab) AND (“PARP inhibitor” OR olaparib OR niraparib OR rucaparib OR talazoparib OR veliparib)). This evidence concerns the gene CD274 and female reproductive organ cancer.